New hope for kids with Tough-to-Treat hodgkin lymphoma
NCT ID NCT01920932
Summary
This study tested a new combination of treatments for children and teens with high-risk Hodgkin lymphoma. Researchers replaced one standard chemotherapy drug with a targeted antibody drug (brentuximab vedotin) to see if it works better and reduces the need for radiation. The goal was to improve survival and quality of life compared to older treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II CHILDHOOD HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Harvard Cancer Center
Boston, Massachusetts, 02115, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Maine Children's Cancer Program (MCCP)
Scarborough, Maine, 04704, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
St. Jude Midwest Affiliate
Peoria, Illinois, 61637, United States
Conditions
Explore the condition pages connected to this study.